Congrats to Dr S Izuka a clinical Rheumatolgy fellow for making a press release. Looking forward to full presentation next week. We published SLE pts had more adverse drug reactions than RA so I try to avoid sulfa drugs in SLE JRheum 2003;30:480-4 #ACR2020 https://t.co/spr6FsS1xg

• https://twitter.com/janetbirdope/status/1324747149922455558

During virtual meetings👨‍💻 👩‍💻 do you switch on your camera 📷? #Virtual #virtualmeetings

Think of Psoriatic Arthritis in the context of Psoriasis https://t.co/XpTFdzEHEa

• https://twitter.com/PsoriasisUK/status/1323951897288581122

COVID-19 has taught us to embrace virtual education. Viewing over 1700 posters is difficult when we have a big meeting but having virtual platform gives us the opportunity to do this now and interact with the presenters #ACR20 @RheumNow https://t.co/vwiDa34VYY

Honored to have our article "Using questions to enhance #rheumatology education" featured in the Medical Education Year in Review by @LisaCriscione at #ACR20. Read the full article here --> https://t.co/iDVvaxrTl5 #MedEd #rheum https://t.co/y78BP2qkqM

• https://doi.org/10.1002/acr.23753

Check out this session at 4 pm EST today on “Psoriatic Arthritis: Treatment in Practice” detailing emerging therapies and co-management strategies by this amazing team! #ACR20 @RheumNow https://t.co/baNtDLe6Rc

• https://twitter.com/elainehusnimd/status/1324805291263827973

Check https://t.co/FXLHCUIa5v to explore this concept further!

• Penn Inflammation Arthritis Program

It’s that time of day/night at #ACR20, the votes are in, and the people have spoken. Coffee it is @RheumNow https://t.co/XGmnGrPq5F https://t.co/bEoj15HnGl

• https://twitter.com/drdavidliew/status/1324405198068936706

Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors? Can we learn lessons about collaborative work from @rheum_covid? Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy

Inflammation is not a single entity, and the imperative to dissect it carefully is so great in irAEs - in both treatment and measurement. "I'm attempting to stir the pot" - @LCalabreseDO - and there really is plenty to think about. https://t.co/8C6RbMI2l9

One of my #ACR20 highlights about to start - irAE Study Group, hosted by @CCalabreseDO & @NohaMDAnderson Imminent paradigm definition by @LCalabreseDO: one of the biggest challenges in the field: how to target therapies in irAEs, to maintain cancer response #ACR2020 @RheumNow https://t.co/WzFbCc8TuT

Just the beginning... trained over 1397 x-rays, this will only get better. It could either: - stop humans from having to do tedious things - make Sharp/SvdH scores readily available in clinical practice/developing world/consistent in studies. Either way, good! tag @DrCMcMaster

Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update. Beautiful organization of targeted therapy in multiple autoimmune diseases. Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J

Dr. Siri will see you now...🤖 Machine learning identified 9 signatures including nail pso, CRP and 7 biomarkers to distinguish PsA from PsO pts without arthritis and will help diagnose PsA early. ➡️will need to test independent data @RheumNow #ACR20 Abs#0502

Abst#0194 at #ACR20 showed that significant symptoms of depression in RA are more frequent than depression diagnosed clinically, suggesting that depression may go undiagnosed and that symptoms of depression predicted mortality in RA patients! @RheumNow https://t.co/GqwXNB45y2